Cancer biomarker

Over-expression of biomarker predicts outcome in cancer patients

  • Identified common biomarker in multiple cancers, including prostate and HPV-associated cancers
  • Accurate prognosis of slow-growing cancers
  • Stratify or categorize prostate patients for improved therapy strategies
  • Predict cancer recurrence and monitor disease progression


Licensing Manager: Matt Boehm, Ph.D. or 402-559-2166


Better prediction of survival using common cancer biomarker

Vimla Band, Ph.D.

Vimla Band, Ph.D.

Ensuring patient survival and predicting the recurrence of cancer are now possibilities with a recently discovered biomarker at the University of Nebraska Medical Center.
A protein found in various cancer tissues could aid in diagnosing cancer and more accurately determine a patient’s prognosis. According to new research, the biomarker’s overexpression in developing and late stage cancer correlates with reduced overall survival of the patient. Ensuring a better prognosis and increasing the odds of survival depends on what stage in the cancer’s development the malignancy is detected.
Most types of cancer do not display symptoms until reaching advanced and more aggressive stages. Early detection of the cancerous growth is essential for increasing the overall survival of the patient.
In an alternative form, the detected cancer can be inactive (non-progressing) or slow growing. Doctors may prescribe for the cancer to be monitored and remain untreated. In contrast, some patients are prematurely assigned unnecessary treatments that may result in unfortunate side effects. The identified biomarker could serve to better stratify or categorize patients with inactive or slow growing forms of prostate cancer and improve strategies to treat patients.
More than ever, researchers are striving to identify biomarkers that can more effectively diagnose and stage cancer. As an additional prognostic biomarker, the identified protein could accurately stratify patients with inactive or slow growing cancer, aid in determining appropriate treatment options, and serve as the most significant marker for predicting cancer recurrence in patients.
To discuss licensing opportunities please contact Matt Boehm, Ph.D., at or 402-559-2166.